Adult Clinical Trials

BMT and Cellular Therapies

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact the BMT and Cellular Therapies Clinical Trials Office at 919.681.5027.

11 trials identified.

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Phase: Phase III
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Gwynn Long
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.668.6524
Reference Number: 00027023
View this trial at ClinicalTrials.gov

A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care
Phase: N/A
Sponsor: PI initiated
Principal Investigator: Nelson Chao
Contact: Krista Rowe
Phone: 919.681.5027
Reference Number: 00032263

A Multi-Center Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome BMT CTN Protocol 1102
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Mitchell Horwitz
Contact: BMT Cell Therapy Oncology Research Team
Phone: 919.681.5027
Reference Number: 00050652
View this trial at ClinicalTrials.gov

Patient-Centered Home-Based Hematopoietic Stem Cell Transplantation
Phase: N/A
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Nelson Chao
Contact: BMT Cell Therapy Oncology Research Team
Phone: 919.668.1002
Reference Number: 00051024
View this trial at ClinicalTrials.gov

A Phase II Trial for the prevention of gastrointestinal toxicity from total body irradiation or high dose chemotherapy with pasireotide
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Anthony Sung
Contact: BMT Cell Therapy Oncology Research Team
Phone: 919.681.5027
Reference Number: 00051736
View this trial at ClinicalTrials.gov

A RANDOMIZED PHASE II TRIAL TO EVALUATE PROGRESSION-FREE SURVIVAL RATES IN PATIENTS RECEIVING NK CELL-ENRICHED DONOR CELL INFUSIONS WHEN ADMINISTERED ALONE OR ADMINISTERED WITH THE TLR9 AGONIST, DUK-CPG-001, FROM A 4-6/8 HLA-MATCHED RELATED OR 7-8/8 HLA-MATCHED DONOR FOLLOWING REDUCED INTENSITY OR NON-ABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.5027
Reference Number: 00057501
View this trial at ClinicalTrials.gov

A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus Host-Disease
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Mitchell Horwitz
Contact: BMT Oncology Clinical Trials Office
Phone: 919.681.5027
Reference Number: 00058005
View this trial at ClinicalTrials.gov

Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Cristina Gasparetto
Contact: BMT Oncology Clinical Trials Office
Phone: 919.681.5027
Reference Number: 00063517
View this trial at ClinicalTrials.gov

A Phase I Trial of Fostamatinib and Chronic Graft-vs.-Host Disease Development after Allogeneic Stem Cell Transplantation
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Stefanie Sarantopoulos
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.684.7115
Reference Number: 00064227
View this trial at ClinicalTrials.gov

A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Mitchell Horwitz
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.5027
Reference Number: 00072499
View this trial at ClinicalTrials.gov

A Phase I/II Study of Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT HEME Malignancy Clinical Trials Oncology Office
Phone: 919.681.4769
Reference Number: 00077145
View this trial at ClinicalTrials.gov